$3.00 -$0.06 (-2.0%)

04:00 PM EDT on 10/18/19

Acer Therapeutics Inc (NASDAQ:ACER)

CAPS Rating: 1 out of 5

A biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular disease.

Current Price $3.00 Mkt Cap $30.3M
Open $3.24 P/E Ratio 0.00
Prev. Close $3.06 Div. (Yield) $0.00 (0.0%)
Daily Range $2.96 - $3.32 Volume 52,002
52-Wk Range $1.87 - $28.25 Avg. Daily Vol. 89,950

Caps

How do you think NASDAQ:ACER will perform against the market?

Add Stock to CAPS Watchlist

All Players

33 Outperform
24 Underperform
 

All-Star Players

4 Outperform
20 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ACER Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

whoodatstockhot (80.77)
Submitted August 07, 2013

Cutting edge research being completed at Opexa, huge buyout potential here, one of those specs that could change how MS is treated. Balance sheet strong, low risk of secondary. Great risk reward, with over 500% upisde quite possible for long-term… More

jed71 (99.87)
Submitted November 07, 2016

Well, this certainly seems to shed light on some of their problems: "Opexa Therapeutics reduces workforce by 40% in light of the negative Phase 2b Abili-T clinical trial top-line results announced on October 28""Following further analysis of the… More

NASDAQ:ACER VS S&P 500 (SPY)

Fools bullish on NASDAQ:ACER are also bullish on:

Fools bearish on NASDAQ:ACER are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about ACER.

Recs

3
Member Avatar jed71 (99.87) Submitted: 11/7/2016 10:24:32 AM : Underperform Start Price: $7.11 NASDAQ:ACER Score: +98.66

Well, this certainly seems to shed light on some of their problems:

"Opexa Therapeutics reduces workforce by 40% in light of the negative Phase 2b Abili-T clinical trial top-line results announced on October 28"

"Following further analysis of the Phase 2b Abili-T clinical trial top-line results and in order to reduce operating expenses and conserve cash resources, on October 26, 2016, the Company's Board of Directors approved reduction of the Company's 20 current full-time employees. The workforce reduction is effective immediately. The Company estimates that it will incur incremental aggregate cash charges of approximately $95,000 associated with this workforce reduction. The Company also announced that it had accepted the resignation of Donna Rill, the Company's Chief Development Officer, with such resignation to be effective as of November 4, 2016."

I expect a reverse split will follow shortly, as well as a new cash raise after the reverse split takes place. That's assuming they can find anyone to sell additional shares to, which seems to be a bit of a stretch here. A little more dangerous than my normal red thumbs, but this should move much lower over the next 12 months or so. Target under $0.10 pre-split.

Recs

0
Member Avatar allstar31 (99.89) Submitted: 9/12/2014 11:14:52 PM : Underperform Start Price: $111.01 NASDAQ:ACER Score: +147.04

Uses known stock pump and dumper Redchip.com for PR purposes. Garbage.

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 11/15/2013 3:00:17 PM : Outperform Start Price: $189.70 NASDAQ:ACER Score: -164.26

One massive IHS on monhtly

Leaderboard

Find the members with the highest scoring picks in ACER.

Score Leader

whatsthepoint

whatsthepoint (99.98) Score: +377.17

The Score Leader is the player with the highest score across all their picks in ACER.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MaxPwr273 72.06 10/26/2011 Underperform 5Y $364.50 -99.18% +139.25% +238.42 0 Comment
2011Fool 97.12 2/18/2011 Underperform NS $632.90 -99.53% +121.94% +221.47 0 Comment
Halffrenzy 25.81 3/13/2013 Underperform 5Y $178.11 -98.32% +91.46% +189.78 0 Comment
saab93boi 22.24 3/26/2013 Underperform 3W $211.24 -98.58% +91.08% +189.66 0 Comment
Mary953 84.34 3/25/2013 4/6/2018 Underperform 5Y $173.14 -98.27% +91.15% +189.42 0 Comment
stockjock11 < 20 5/22/2013 Underperform 5Y $138.34 -97.83% +76.96% +174.80 0 Comment
allstar31 99.89 9/15/2014 Underperform 5Y $111.01 -97.30% +49.74% +147.04 1 Comment
zzlangerhans 99.82 10/31/2016 Underperform 1Y $8.80 -65.92% +40.30% +106.22 0 Comment
thehammer01 98.23 11/30/2016 Underperform 5Y $9.73 -69.18% +35.12% +104.31 0 Comment
tsperbeck 99.73 2/3/2017 Underperform 5Y $10.44 -71.25% +30.06% +101.32 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackMDB < 20 2/20/2007 Outperform NS $1,457.98 -85.91% -5.14% -80.77 4/17/2012 @ $205.41 0 Comment